Search

Displaying all 9 results
  1. Pathway

    Doxycycline Action Pathway

    smpdb.ca/view/SMP0000291
    Drug action

    Doxycycline is a long-acting tetracycline derived from oxytetracycline. Like minocycline, it is lipophilic and can diffuse through the lipid bilayer of bacteria. … Doxycycline reversibly binds to the bacterial 30S ribosomal subunit and to a lesser extent the 50S subunit, blocking the binding of aminoacyl tRNA to the A site on the ribosome-RNA complex.

    Drugs: Doxycycline
  2. Pathway

    Doxycycline Predicted Metabolism Pathway

    smpdb.ca/view/SMP0174526
    Metabolic

    Metabolites of Doxycycline are predicted with biotransformer.

    Drugs: Doxycycline · Mesoheme
  3. Pathway

    Mucopolysaccharidosis VII. Sly Syndrome

    smpdb.ca/view/SMP0000556
    Disease

    Mucopolysaccharidosis type VII (MPS VII), also called Sly syndrome, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by mutations in the GUSB gene. … It is estimated that MPS VII affects 1 in 250,000 individuals.  

    Drugs: Pyridoxal phosphate · NADH · ATP · Calcium · Magnesium cation · Uridine diphosphate glucose +4 more
  4. Pathway

    Mucopolysaccharidosis VII. Sly Syndrome

    smpdb.ca/view/SMP0125762
    Disease

    It is estimated that MPS VII affects 1 in 250,000 individuals. … Mucopolysaccharidosis type VII (MPS VII), also called Sly syndrome, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by mutations in the GUSB gene.

    Drugs: Pyridoxal phosphate · NADH · ATP · Calcium · Magnesium cation · Uridine diphosphate glucose +4 more
  5. Pathway

    Glycogenosis, Type VII. Tarui Disease

    smpdb.ca/view/SMP0000531
    Disease

    Glycogen storage disease, Type VII, also called GSD VII and Tarui Disease, is an inborn error of metabolism (IEM) and metabolic disorder caused by a defective 6-phosphofructokinase. 6-phosphofructokinase … Currently, the major treatment for Glycogen storage disease, Type VII is associated with diet management.

    Drugs: Pyruvic acid · NADH · ATP · Potassium cation · Magnesium cation · 2-phospho-D-glyceric acid +3 more
  6. Pathway

    Glycogenosis, Type VII. Tarui Disease

    smpdb.ca/view/SMP0125707
    Disease

    Glycogen storage disease, Type VII, also called GSD VII and Tarui Disease, is an inborn error of metabolism (IEM) and metabolic disorder caused by a defective 6-phosphofructokinase. 6-phosphofructokinase … Currently, the major treatment for Glycogen storage disease, Type VII is associated with diet management.

    Drugs: Pyruvic acid · NADH · ATP · Potassium cation · Magnesium cation · 2-phospho-D-glyceric acid +3 more
  7. Pathway

    Coagulation Factor VII Human Action Pathway

    smpdb.ca/view/SMP0126839
    Drug action

    It is broken down via catabolism in the body. … Coagulation factor VII human is a coagulation factor also known as Balfaxar, Beriplex, Kcentra and Octaplex to treat hemophilia and Glanzmann's thrombasthenia.

    Drugs: Calcium · Coagulation factor VII human
  8. Pathway

    Glycogenosis, Type VI. Hers Disease

    smpdb.ca/view/SMP0125761
    Disease

    Glycogen storage disease type VI has been reported in approximately 11 people at least. … Glycogen storage disease type VI, also called GSDVI or Hers disease, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by a defective liver glycogen phosphorylase.

    Drugs: Pyridoxal phosphate · NADH · ATP · Calcium · Magnesium cation · Uridine diphosphate glucose +4 more
  9. Pathway

    Glycogenosis, Type VI. Hers Disease

    smpdb.ca/view/SMP0000555
    Disease

    Glycogen storage disease type VI has been reported in approximately 11 people at least. … Glycogen storage disease type VI, also called GSDVI or Hers disease, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by a defective liver glycogen phosphorylase.

    Drugs: Pyridoxal phosphate · NADH · ATP · Calcium · Magnesium cation · Uridine diphosphate glucose +4 more